All Hong Kong stocks quotes are at least 15 minutes delayed.
02126
JW THERAP-B
HKD
2.3000.070
(3.14%)
1D
AI Analysis
High
2.310
Open
2.250
VWAP
2.28
Vol
361.00K
Mkt Cap
1.26B
Low
2.250
Amount
824.33K
EV/EBITDA(TTM)
--
Total Shares
416.47M
EV
80.56M
EV/OCF(TTM)
--
P/S(TTM)
4.77
JW (Cayman) Therapeutics Co Ltd is a company primarily engaged in research and development, manufacturing, and marketing of cellular immunotherapy products. The Company has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. The Company’s main product, Carteyva, is an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) cell immunotherapy product independently developed by the Company based on a CAR-T cell process platform of Juno (a Bristol Myers Squibb company). The Company mainly conducts its business in the domestic market.
Show More
News
Money Flow
Over the past 66 trading days, overall net money flow is -4.05M, with retail investors contributing 36.77K and major investors adding -3.85M.
Net Buy $ Volume
Net Sell $ Volume
No data
Valuation Metrics
Forward PE
N/A
5Y Average PE
-3.93
Current PE
-2.53
Overvalued PE
1.11
Undervalued PE
-8.97
Forward EV/EBITDA
N/A
5Y Average EV/EBITDA
-2.87
Current EV/EBITDA
-2.14
Overvalued EV/EBITDA
3.30
Undervalued EV/EBITDA
-9.04
Forward PS
N/A
5Y Average PS
14.28
Current PS
3.49
Overvalued PS
44.29
Undervalued PS
-15.73
Financials
AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly
No data
No data
People Also Watch